New targeted drug shows promise for Hard-to-Treat cancers in early trial
NCT ID NCT06235983
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested an experimental drug called LY3537982 in 12 Chinese patients with advanced solid tumors that have a specific KRAS G12C mutation. The main goal was to measure how the drug moves through the body and to check its safety. Researchers also looked for signs that the drug might shrink tumors, but this is not a cure and ongoing treatment may be needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jilin Cancer Hospital
Changchun, Jilin, 132000, China
-
The First Affiliated Hospital, Zhejiang University
Hangzhou, Zhejiang, 310003, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.